Navigating Health Canada's New Medical Device Licence Application Process Effective February 2026

Health Canada has introduced significant changes to the Medical Device Licence (MDL) application process, effective February 2, 2026. These updates come with the release of version 5 of the Guidance on Managing Applications for Medical Device Licences, published on November 21, 2025. The new guidance replaces the 2020 version and brings stricter timelines, enhanced screening procedures, and a revised reconsideration process. For manufacturers and stakeholders in the medical device industry, understanding these changes is essential to ensure smooth regulatory compliance and timely approvals.

This post breaks down the key updates, explains why they matter, and offers practical advice on adapting to the new system.

What Has Changed in the Medical Device Licence Application Process?

The updated guidance introduces several important modifications that affect how manufacturers submit and manage their MDL applications. The most notable changes include:

• Mandatory use of the Regulatory Enrolment Process (REP)

All applications for Class II, III, and IV medical devices must now go through REP. This replaces previous submission methods, such as email, and requires manufacturers to register and manage their applications digitally.

• Submission through the Common Electronic Submission Gateway (CESG)

Health Canada requires all Class II–IV device applications to be submitted via CESG. This centralized portal streamlines document handling but demands new technical workflows from applicants.

• Stricter timelines for review and deficiency responses

The guidance sets tighter deadlines for Health Canada’s review stages and for manufacturers to respond to deficiency letters. This means manufacturers must prepare to act faster and more efficiently.

• Enhanced screening procedures

Health Canada will conduct more thorough initial screenings to identify incomplete or non-compliant applications early. This aims to reduce delays caused by back-and-forth communications.

• Revised reconsideration process

The process for requesting reconsideration of decisions has been updated to clarify timelines and submission requirements, making it more structured and transparent.

Why These Changes Matter to Manufacturers

The new process affects every stage of the MDL application journey. Here’s why manufacturers should pay close attention:

• Transition from email to digital portals requires new skills and systems

Many manufacturers have relied on email submissions. Moving to REP and CESG means investing in digital infrastructure and training staff on new platforms.

• Faster timelines demand better internal coordination

The shortened deadlines for responding to Health Canada’s requests mean manufacturers must streamline internal review and approval processes to avoid missing critical dates.

• Increased risk of application rejection at screening

With enhanced screening, incomplete or poorly prepared applications face higher chances of rejection or delays. Manufacturers must ensure all documents meet Health Canada’s standards before submission.

• Clearer reconsideration rules help manage appeals

Understanding the revised reconsideration process allows manufacturers to plan appeals more effectively and avoid procedural errors.

How to Prepare for the New MDL Application Process

Adapting to these changes requires a strategic approach. Here are practical steps manufacturers can take:

1. Register and Familiarize with REP and CESG

• Create REP accounts early

Manufacturers should register their organizations in the Regulatory Enrolment Process well before February 2026 to avoid last-minute issues.

• Train staff on CESG submission protocols

Understanding how to prepare and upload documents correctly is critical. Health Canada provides user guides and webinars that can help.

2. Review and Update Internal Workflows

• Set clear timelines for document preparation and review

Align internal deadlines with Health Canada’s stricter timelines to ensure timely responses.

• Assign dedicated teams for regulatory submissions

Having a focused team reduces errors and speeds up communication.

3. Conduct Thorough Pre-Submission Checks

• Use Health Canada’s checklists and templates

These tools help ensure applications are complete and compliant.

• Perform internal audits of submission packages

Double-checking documents before submission reduces the risk of screening rejections.

4. Plan for Faster Deficiency Responses

• Develop rapid response protocols

Prepare to quickly gather missing information or clarify issues raised by Health Canada.

• Maintain clear communication channels

Ensure that regulatory, quality, and technical teams can collaborate efficiently.

5. Understand the Reconsideration Process

• Familiarize with new timelines and requirements

Knowing when and how to submit reconsideration requests can save valuable time.

• Prepare detailed and well-supported appeals

Clear documentation and justification improve chances of success.

Examples of How These Changes Impact Manufacturers

Consider a mid-sized medical device company preparing to submit a Class III device licence application:

• Before February 2026

The company submitted applications via email and had up to 90 days to respond to deficiency letters. Their regulatory team was small and handled submissions alongside other duties.

• After February 2026

The company must submit through CESG and use REP. The response time for deficiencies is reduced to 30 days. To comply, the company hires a dedicated regulatory specialist and invests in training on the new digital systems. They also implement a checklist system to ensure all documents meet Health Canada’s requirements before submission.

This example shows how the new process requires companies to be more organized and proactive.

Tips for Smooth Transition and Compliance

• Start early

Don’t wait until the last minute to register for REP or learn CESG submission procedures.

• Engage with Health Canada resources

Use official webinars, FAQs, and guidance documents to stay informed.

• Collaborate across departments

Regulatory, quality assurance, and product development teams must work closely to meet deadlines.

• Keep detailed records

Document all communications and submissions to track progress and support reconsideration requests if needed.

• Seek expert advice if necessary

Regulatory consultants can help navigate complex requirements and avoid costly mistakes.

The updated Medical Device Licence application process reflects Health Canada’s commitment to improving regulatory efficiency and patient safety. Manufacturers who adapt quickly and thoroughly will benefit from smoother application experiences and faster approvals. The key is to embrace the digital submission platforms, respect the new timelines, and maintain high standards for application quality.

By preparing now, manufacturers can avoid disruptions and continue bringing safe, effective medical devices to the Canadian market.